A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer Article Early Access

Industry Collaboration International Collaboration

cited authors

  • Cho, Byoung Chul; Goldberg, Sarah B.; Kim, Dong-Wan; Socinski, Mark A.; Burns, Timothy F.; Lwin, Zarnie; Pathan, Nuzhat; Ma, Wei Dong; Masters, Joanna C.; Cossons, Nandini; Wilner, Keith; Nishio, Makoto; Husain, Hatim

authors

Publication Date

  • June 5, 2022

webpage

published in

category

keywords

  • (5-8)
  • 2 study
  • PF-06747775
  • advanced non-small cell lung cancer
  • epidermal growth factor receptor
  • phase 1
  • tyrosine kinase inhibitor